MaltSci 麦伴科研

Appearance

Popular Reports / reproductive-medicine

This report is written by MaltSci based on the latest literature and research findings

How does polycystic ovary syndrome affect fertility? ​

Abstract ​

Polycystic Ovary Syndrome (PCOS) is a prevalent endocrine disorder affecting 5-10% of reproductive-aged women, significantly impacting fertility through hormonal imbalances and metabolic dysfunctions. The disorder is characterized by irregular menstrual cycles, hyperandrogenism, and anovulation, which collectively contribute to infertility. Hormonal dysregulation within the hypothalamic-pituitary-ovarian (HPO) axis, particularly elevated luteinizing hormone (LH) levels and insulin resistance, exacerbates reproductive challenges. Additionally, metabolic disturbances associated with obesity further complicate fertility outcomes in women with PCOS. The clinical manifestations of PCOS, including hirsutism and acne, are also linked to reduced fertility potential. Treatment strategies encompass lifestyle modifications aimed at weight management, pharmacological interventions such as metformin and clomiphene citrate, and assisted reproductive technologies (ART). Emerging research highlights the importance of understanding the genetic underpinnings of PCOS and its long-term health implications, including increased risks of cardiovascular diseases and psychological distress. This review emphasizes the need for a comprehensive approach to managing PCOS, focusing on both reproductive and metabolic health to improve outcomes for affected women.

Outline ​

This report will discuss the following questions.

  • 1 Introduction
  • 2 Pathophysiology of PCOS
    • 2.1 Hormonal Imbalances
    • 2.2 Metabolic Dysfunction
  • 3 Clinical Manifestations of PCOS
    • 3.1 Irregular Menstrual Cycles
    • 3.2 Hyperandrogenism
  • 4 Impact of PCOS on Fertility
    • 4.1 Anovulation and Infertility
    • 4.2 Effects on Ovarian Reserve
  • 5 Treatment Strategies for Improving Fertility
    • 5.1 Lifestyle Modifications
    • 5.2 Pharmacological Interventions
    • 5.3 Assisted Reproductive Technologies
  • 6 Future Directions in Research
    • 6.1 Emerging Therapies
    • 6.2 Long-term Health Implications
  • 7 Conclusion

1 Introduction ​

Polycystic Ovary Syndrome (PCOS) is a multifaceted endocrine disorder affecting approximately 5-10% of women of reproductive age, characterized by a combination of reproductive and metabolic dysfunctions, including irregular menstrual cycles, hyperandrogenism, and polycystic ovaries [1][2]. The implications of PCOS extend beyond the clinical symptoms, significantly impacting fertility and overall reproductive health. Anovulation, a common consequence of PCOS, is recognized as one of the leading causes of infertility among women [3][4]. Therefore, understanding the intricate relationship between PCOS and fertility is paramount for developing effective treatment strategies and improving reproductive outcomes for affected individuals.

The significance of researching PCOS lies in its prevalence and the profound effects it has on women's health. Beyond infertility, women with PCOS face increased risks of metabolic syndrome, cardiovascular diseases, and psychological distress [2][5]. Moreover, the chronic nature of PCOS necessitates a comprehensive approach to management that addresses not only reproductive health but also associated metabolic and psychosocial factors [6]. Given these considerations, it is crucial to explore the underlying mechanisms through which PCOS affects fertility, including hormonal imbalances, metabolic dysfunction, and lifestyle factors.

Current research has illuminated various aspects of PCOS and its impact on fertility. Studies have highlighted that hormonal dysregulation, particularly elevated androgen levels and insulin resistance, play critical roles in the pathophysiology of PCOS and its association with infertility [7][8]. Additionally, the metabolic disturbances linked to PCOS, such as obesity and insulin resistance, further exacerbate fertility issues [1][4]. Furthermore, emerging evidence suggests that lifestyle modifications, pharmacological interventions, and assisted reproductive technologies can enhance fertility outcomes for women with PCOS [9][10].

This review is organized into several key sections to provide a comprehensive overview of how PCOS affects fertility. The first section will delve into the pathophysiology of PCOS, examining hormonal imbalances and metabolic dysfunction. The subsequent section will discuss the clinical manifestations of PCOS, focusing on irregular menstrual cycles and hyperandrogenism. Following this, we will explore the specific impacts of PCOS on fertility, including anovulation and its effects on ovarian reserve. The review will then address treatment strategies aimed at improving fertility outcomes, highlighting lifestyle modifications, pharmacological interventions, and the role of assisted reproductive technologies. Finally, we will outline future directions in research, emphasizing emerging therapies and the long-term health implications for women with PCOS.

In summary, understanding the relationship between PCOS and fertility is essential for developing targeted interventions and improving the quality of life for affected women. By synthesizing existing research and identifying gaps in knowledge, this review aims to contribute to the ongoing discourse on PCOS and its implications for reproductive health.

2 Pathophysiology of PCOS ​

2.1 Hormonal Imbalances ​

Polycystic ovary syndrome (PCOS) is a complex endocrine disorder that significantly impacts fertility through various hormonal imbalances and metabolic dysfunctions. The condition is characterized by chronic anovulation, hyperandrogenism, and ovarian dysfunction, which together contribute to reproductive challenges.

The pathophysiology of PCOS involves a dysregulation of the hypothalamic-pituitary-ovarian (HPO) axis, leading to altered gonadotropin secretion. In women with PCOS, there is often an imbalance in luteinizing hormone (LH) and follicle-stimulating hormone (FSH) levels. Typically, elevated LH levels relative to FSH can result in anovulation and disrupted ovarian follicle development. This imbalance is compounded by excessive androgen production from the ovaries and adrenal glands, which can interfere with normal folliculogenesis and inhibit the maturation of ovarian follicles, ultimately leading to the formation of multiple cysts in the ovaries [11].

Furthermore, insulin resistance is a prevalent feature in 50-70% of individuals with PCOS, contributing to hyperinsulinemia, which exacerbates ovarian dysfunction. Elevated insulin levels can enhance androgen production by the ovaries, further disrupting the normal hormonal milieu necessary for ovulation [12]. This insulin-related hyperandrogenism is linked to a range of reproductive issues, including irregular menstrual cycles and infertility.

The consequences of these hormonal imbalances manifest in various ways. Women with PCOS often experience anovulation, which is a primary contributor to infertility. The condition is one of the leading causes of anovulatory infertility globally [2]. Additionally, the presence of hyperandrogenism can lead to clinical symptoms such as hirsutism, acne, and obesity, which may further complicate the reproductive landscape [13].

Moreover, the metabolic implications of PCOS, including obesity and associated cardiovascular risks, can further impact fertility outcomes. Obesity not only exacerbates the hormonal disturbances associated with PCOS but also negatively affects ovulatory function and overall reproductive health [14].

In conclusion, PCOS affects fertility primarily through hormonal imbalances that disrupt the normal ovulatory process. The interplay between hyperandrogenism, insulin resistance, and metabolic dysfunction creates a multifaceted challenge for women with this syndrome, necessitating a comprehensive approach to diagnosis and management to optimize reproductive outcomes.

2.2 Metabolic Dysfunction ​

Polycystic ovary syndrome (PCOS) is a prevalent endocrine and metabolic disorder affecting approximately 11-13% of women of reproductive age, and it is recognized as one of the most common causes of infertility due to anovulation in this population. The pathophysiology of PCOS is multifaceted, involving various hormonal and metabolic disturbances that significantly impact fertility.

A key feature of PCOS is hyperandrogenemia, which is characterized by elevated levels of androgens, leading to symptoms such as hirsutism, acne, and menstrual irregularities. This hormonal imbalance is often accompanied by insulin resistance, which is present in a significant proportion of women with PCOS. Insulin resistance can exacerbate hyperandrogenism by stimulating ovarian theca cells to produce more androgens, thereby creating a vicious cycle that further disrupts ovulatory function [13].

Obesity, which is increasingly common among women with PCOS, plays a crucial role in exacerbating metabolic dysfunction. It has been shown to worsen the hyperandrogenic state and insulin resistance, leading to poorer menstrual and ovulatory performance. Women with obesity and PCOS experience more severe reproductive and metabolic complications compared to their normal-weight counterparts, ultimately resulting in lower pregnancy rates [15].

Moreover, the presence of metabolic syndrome, characterized by a cluster of conditions including obesity, dyslipidemia, and hypertension, is frequently observed in women with PCOS. These metabolic abnormalities can further compromise fertility by affecting the quality of oocytes and the overall reproductive environment [16].

Research has indicated that oxidative stress and energy metabolism abnormalities are also pivotal contributors to the reproductive dysfunction seen in PCOS. Mitochondrial dysfunction and increased oxidative stress in granulosa cells lead to impaired follicular development and compromised oocyte quality, which are critical for successful fertilization and pregnancy [17].

Additionally, recent studies have highlighted the potential role of epigenetic factors in the inheritance of PCOS traits, suggesting that metabolic dysfunctions associated with PCOS may not only affect the individual but could also have implications for offspring, potentially influencing their reproductive health as well [15].

In summary, the metabolic dysfunction associated with PCOS, characterized by insulin resistance, obesity, and oxidative stress, plays a significant role in impairing fertility. These factors disrupt normal ovarian function, leading to anovulation and reduced fertility rates among affected women. Understanding these underlying mechanisms is crucial for developing effective therapeutic strategies aimed at improving reproductive outcomes in women with PCOS.

3 Clinical Manifestations of PCOS ​

3.1 Irregular Menstrual Cycles ​

Polycystic ovary syndrome (PCOS) is a complex endocrine disorder that significantly impacts fertility, particularly through its association with irregular menstrual cycles. The clinical manifestations of PCOS include reproductive and metabolic disturbances, with irregular menstrual cycles being a hallmark symptom. In women with PCOS, the condition is characterized by hyperandrogenism, ovulatory dysfunction, and polycystic ovarian morphology, which together contribute to infertility issues.

Irregular menstrual cycles in women with PCOS often result from anovulation or oligo-ovulation, which means that ovulation occurs infrequently or not at all. This irregularity can lead to longer time to pregnancy (TTP) and is associated with reduced fertility rates. In a case-control study by Hassan and Killick (2003), it was observed that women with polycystic ovaries who exhibited additional symptoms such as obesity, menstrual disturbances, hirsutism, and acne had significantly longer TTP and were at a higher risk of subfertility. Specifically, the relative risk (RR) of subfertility increased to 2.6 for obese women, 4.6 for those with menstrual disturbances, and 2.5 for those with hirsutism[1].

Furthermore, the evolutionary implications of PCOS suggest that the disorder is the most common cause of ovarian infertility globally, affecting approximately 5-10% of reproductive-aged women. The metabolic disturbances linked with PCOS, including insulin resistance, exacerbate the reproductive issues, leading to a self-perpetuating cycle of dysfunction[3].

In terms of clinical management, it is critical to recognize that the mere appearance of polycystic ovaries on ultrasound does not inherently indicate subfertility. As demonstrated in the findings of Hassan and Killick, women with polycystic ovaries but without symptomatic features did not exhibit a significantly longer TTP compared to those with normal ovaries. This highlights the importance of considering additional diagnostic criteria beyond ultrasound morphology when evaluating fertility potential in women with PCOS[1].

Moreover, the metabolic profile of women with PCOS, particularly those who are obese or exhibit insulin resistance, plays a crucial role in their reproductive health. The relationship between hyperandrogenism and ovulatory dysfunction is complex, and addressing metabolic abnormalities is essential for improving fertility outcomes in this population[14].

In conclusion, PCOS affects fertility primarily through the mechanism of irregular menstrual cycles and anovulation, compounded by associated metabolic disturbances. A comprehensive approach that includes lifestyle modifications, metabolic management, and individualized treatment plans is essential for enhancing reproductive outcomes in women affected by PCOS.

3.2 Hyperandrogenism ​

Polycystic ovary syndrome (PCOS) is a multifaceted endocrine disorder that significantly impacts fertility, primarily through its association with hyperandrogenism, which is a key clinical manifestation of the condition. Hyperandrogenism in PCOS is characterized by elevated levels of androgens, which can lead to various reproductive and metabolic disturbances.

The prevalence of hyperandrogenism in women with PCOS is notably high, contributing to a range of symptoms including hirsutism, acne, and menstrual irregularities. These symptoms are often linked to anovulation, which is a common cause of infertility in women with PCOS. In fact, hyperandrogenism is a major factor in the pathophysiology of PCOS, affecting ovarian function and leading to disrupted folliculogenesis. Studies have shown that women with elevated androgen levels may experience longer times to pregnancy (TTP) and higher rates of subfertility. For instance, a case-control study indicated that women with polycystic ovaries (PCOs) who also presented with symptoms such as obesity and menstrual disturbances had significantly reduced fertility outcomes, with relative risks (RR) for subfertility ranging from 2.5 to 4.6 depending on the number of symptoms present [1].

Furthermore, hyperandrogenemia is not only linked to reproductive issues but also has implications for metabolic health, which can further exacerbate fertility challenges. Women with PCOS often exhibit insulin resistance, which is associated with obesity and can lead to metabolic syndrome. This combination of hyperandrogenism and insulin resistance can create a vicious cycle that further impairs reproductive function [[pmid:23352610],[pmid:14671172]].

Research involving animal models has further elucidated the detrimental effects of hyperandrogenism on fertility. For example, studies in female macaques have demonstrated that chronic hyperandrogenemia, particularly in conjunction with a Western-style diet, can lead to increased metabolic dysfunction and reduced fertility [7]. This highlights the importance of managing hyperandrogenism not only for improving reproductive outcomes but also for overall metabolic health.

In summary, hyperandrogenism plays a critical role in the fertility challenges faced by women with PCOS. The interplay between elevated androgen levels, metabolic disturbances, and reproductive function underscores the need for comprehensive management strategies that address both hormonal and metabolic aspects of the syndrome. Effective treatment options may include lifestyle modifications, pharmacological interventions aimed at reducing androgen levels, and addressing insulin resistance to enhance fertility outcomes in affected women [[pmid:37935839],[pmid:35459945]].

4 Impact of PCOS on Fertility ​

4.1 Anovulation and Infertility ​

Polycystic ovary syndrome (PCOS) is a prevalent endocrine disorder that significantly impacts fertility, primarily through mechanisms associated with anovulation. Anovulation, defined as the absence of ovulation, is a key characteristic of PCOS and a leading cause of infertility in affected women. The clinical features of PCOS include hyperandrogenism, chronic anovulatory cycles, and oligomenorrhea or amenorrhea, which collectively contribute to reduced fertility rates (Palomba et al. 2004; Nardo et al. 2008).

The pathophysiology of anovulation in PCOS is complex and multifactorial. It is associated with hormonal imbalances, particularly elevated levels of androgens and insulin resistance, which disrupt the normal ovarian function. The presence of increased anti-Müllerian hormone (AMH) levels is notable in women with PCOS, as it may inhibit the actions of follicle-stimulating hormone (FSH), which is crucial for follicular development and ovulation (Homburg and Crawford 2014). The accumulation of pre-antral and antral follicles in the ovaries, often observed in PCOS, further complicates ovulation dynamics, leading to a functional hyperandrogenic state that adversely affects oocyte quality and competence (Palomba et al. 2017).

The impact of obesity, a common comorbidity in women with PCOS, exacerbates the condition. Obesity is linked to worsened hyperandrogenic and metabolic states, poorer menstrual and ovulatory performance, and ultimately lower pregnancy rates (Pasquali et al. 2006). Lifestyle interventions that promote weight loss have been shown to improve metabolic alterations and enhance ovulatory function, thereby increasing fertility potential in these women.

Moreover, the increased oxidative stress associated with PCOS has been implicated in altered ovarian steroidogenesis and impaired oocyte quality. Elevated oxidative stress levels can lead to mitochondrial dysfunction in granulosa cells, which is critical for proper follicular development and oocyte maturation (Gao et al. 2023). The resultant decline in oocyte competence contributes to the challenges faced by women with PCOS in achieving pregnancy.

In summary, PCOS affects fertility primarily through anovulation, influenced by hormonal imbalances, obesity, and oxidative stress. These factors collectively impair ovarian function and reduce the likelihood of successful conception, highlighting the need for targeted therapeutic strategies to manage these challenges in women with PCOS.

4.2 Effects on Ovarian Reserve ​

Polycystic ovary syndrome (PCOS) significantly impacts fertility through various mechanisms that affect ovarian function and reserve. It is characterized by menstrual irregularity, hyperandrogenism, chronic anovulation, and the presence of enlarged ovaries with multiple follicles. These features contribute to a reduced likelihood of spontaneous conception, making PCOS a leading cause of female infertility globally, affecting approximately 5% to 10% of women of reproductive age [14][18].

The disorder is associated with anovulatory cycles, which directly hinder the ability to conceive. Women with PCOS often experience irregular menstrual cycles, leading to infrequent ovulation or complete absence of ovulation (anovulation) [14]. This lack of regular ovulation is a primary reason for the infertility observed in these patients. Furthermore, the hyperandrogenic state prevalent in PCOS can lead to additional complications such as hirsutism and acne, which may indirectly affect reproductive health and self-esteem, potentially impacting fertility outcomes [19].

In terms of ovarian reserve, studies indicate that while women with PCOS may have a higher number of antral follicles, the quality of these follicles may be compromised. For instance, one study highlighted that although serum anti-Müllerian hormone (AMH) levels, which are indicative of ovarian reserve, slightly decrease during testosterone therapy in transgender men with PCOS, they remain within the normal range. This suggests that while the ovarian reserve may be preserved, the overall reproductive function may still be impaired due to other factors associated with PCOS [20].

Moreover, the condition is often linked with metabolic disorders, including insulin resistance and obesity, which can further exacerbate fertility issues. The systemic implications of PCOS include an increased risk of cardiovascular diseases, which can indirectly affect reproductive health by complicating overall health status [18]. The relationship between obesity and PCOS is particularly notable, as weight loss has been shown to restore ovulation in many women, highlighting the importance of metabolic health in managing fertility outcomes [21].

In summary, PCOS affects fertility primarily through its direct impact on ovulation and ovarian reserve, coupled with its association with metabolic and cardiovascular disorders. These multifaceted effects necessitate a comprehensive approach to management, focusing not only on reproductive health but also on addressing metabolic concerns to enhance fertility outcomes in women with PCOS.

5 Treatment Strategies for Improving Fertility ​

5.1 Lifestyle Modifications ​

Polycystic ovary syndrome (PCOS) significantly impacts fertility, primarily due to its association with anovulation and irregular menstrual cycles. The condition is characterized by hyperandrogenism, which can lead to various reproductive issues, including infertility. Lifestyle modifications are increasingly recognized as a crucial initial treatment strategy to improve fertility outcomes in women with PCOS.

Weight management is a key component of lifestyle interventions, as obesity exacerbates the symptoms of PCOS and negatively influences fertility. Dietary changes, physical activity, and behavioral modifications are recommended to achieve and maintain weight loss, which can enhance reproductive health. According to a systematic review, lifestyle interventions have been shown to provide benefits in terms of secondary reproductive outcomes, including reductions in total testosterone levels and improvements in hirsutism and insulin resistance, which are common in women with PCOS (Moran et al., 2011) [22].

Specific findings from studies indicate that lifestyle interventions can lead to significant changes in weight and metabolic parameters. For instance, lifestyle changes resulted in a mean weight loss of approximately 3.47 kg and a reduction in waist circumference by 1.95 cm, alongside improvements in fasting insulin levels (Moran et al., 2011) [22]. Moreover, these interventions have been associated with reductions in the free androgen index, which reflects the hormonal imbalances prevalent in PCOS (Lim et al., 2019) [23].

Dietary modifications, such as adopting a low glycemic index diet, caloric restrictions, and increased intake of high-fiber foods, have been highlighted as effective strategies for improving insulin sensitivity and hormonal balance in women with PCOS. Additionally, engaging in regular physical activity, including both aerobic and resistance exercises, is recommended to enhance metabolic outcomes and support weight management (Gautam et al., 2025) [24].

Despite the positive effects of lifestyle changes on metabolic and hormonal parameters, it is important to note that there is limited evidence regarding their direct impact on primary fertility outcomes such as live birth rates and miscarriage. Most studies have not specifically assessed these outcomes, and further research is needed to evaluate the long-term effects of lifestyle modifications on fertility in women with PCOS (Moran et al., 2011; Lim et al., 2019) [22][23].

In conclusion, while lifestyle modifications play a significant role in managing PCOS and improving various metabolic and reproductive parameters, their direct influence on fertility outcomes remains an area requiring further investigation. Integrating dietary, exercise, and behavioral strategies is essential for optimizing health in women with PCOS and potentially enhancing fertility.

5.2 Pharmacological Interventions ​

Polycystic ovary syndrome (PCOS) significantly impacts fertility through various mechanisms, primarily characterized by irregular menstruation, anovulation, and hormonal imbalances, which collectively contribute to infertility. The pathophysiology of PCOS includes alterations in ovarian morphology, such as the presence of multiple cysts, and hormonal dysregulation leading to elevated androgen levels, which can disrupt normal follicular development and ovulation processes [25].

The infertility associated with PCOS is often attributed to anovulation, where the ovaries fail to release eggs regularly. Women with PCOS frequently experience irregular menstrual cycles due to disrupted folliculogenesis, resulting in incomplete or absent ovulation [26]. Furthermore, the hyperandrogenism characteristic of PCOS can impair the quality of oocytes, further complicating fertility outcomes [27]. Studies indicate that the reproductive potential in women with PCOS varies significantly, depending on the specific phenotype and associated comorbidities [27].

Treatment strategies for improving fertility in women with PCOS predominantly involve pharmacological interventions. Metformin, an insulin sensitizer, has gained recognition as a valuable treatment option, particularly for addressing metabolic disturbances and promoting ovulation [28]. Multiple studies have highlighted metformin's beneficial effects on managing PCOS-associated infertility, pregnancy complications, and enhancing long-term health outcomes [28]. It has been shown to improve insulin sensitivity, which may indirectly enhance ovarian function and restore regular ovulation [26].

In addition to metformin, other pharmacological options include clomiphene citrate, which is often the first-line treatment for inducing ovulation in women with PCOS [29]. This medication works by stimulating the hypothalamus to release gonadotropins, thereby promoting follicular development and ovulation. Moreover, the use of gonadotropins, such as follicle-stimulating hormone (FSH) and luteinizing hormone (LH), is also common in assisted reproductive technologies (ART) to optimize ovarian stimulation and improve chances of conception [30].

Anti-androgenic agents, such as spironolactone, may be employed to manage symptoms of hyperandrogenism, including hirsutism, which can also impact psychological well-being and quality of life, indirectly affecting fertility outcomes [26]. However, it is essential to consider the side effects associated with these medications and their implications for long-term management [26].

Overall, while PCOS poses significant challenges to fertility due to its complex hormonal and metabolic implications, pharmacological interventions, particularly insulin sensitizers like metformin and ovulation-inducing agents, have shown promise in improving reproductive outcomes for affected women. Continued research into the molecular mechanisms underlying PCOS and the development of novel therapeutic targets remain critical for enhancing fertility management strategies [26].

5.3 Assisted Reproductive Technologies ​

Polycystic ovary syndrome (PCOS) significantly impacts fertility through various mechanisms. It is characterized by irregular menstruation, anovulation, and hyperandrogenism, which are critical factors contributing to infertility. In fact, PCOS is associated with approximately 80% of anovulatory infertility cases, yet the precise mechanisms underlying PCOS-induced anovulation remain poorly understood [31]. Women with PCOS often experience disrupted ovulation, incomplete follicular development, and reduced fertility rates, making it a prevalent concern among those of reproductive age [25].

Assisted reproductive technologies (ART) are frequently employed to assist women with PCOS in achieving pregnancy. Most PCOS patients opt for ART due to the challenges posed by their condition. However, optimizing gonadotropin doses—such as follicle-stimulating hormone (FSH) and luteinizing hormone (LH)—to stimulate ovarian response without triggering ovarian hyperstimulation syndrome (OHSS) is a significant challenge [30]. The hormonal imbalances associated with PCOS can impair the metabolic environment critical for oocyte maturation and endometrial receptivity, further complicating fertility outcomes [30].

Current treatment strategies for improving fertility in women with PCOS include lifestyle interventions, pharmacological treatments, and ART. Lifestyle modifications, particularly for overweight women seeking pregnancy, are considered the first-line treatment. Pharmacological agents such as metformin and clomiphene citrate are commonly used to induce ovulation [31]. Additionally, some patients are turning to herbal medicines that have shown potential therapeutic benefits in managing PCOS [31].

In the context of ART, in vitro fertilization (IVF) is a primary method used to enhance pregnancy chances for women with PCOS. However, the traditional IVF approach often leads to an exaggerated ovarian response due to the high doses of gonadotropins required, resulting in the retrieval of immature oocytes and increased risks of complications [32]. An alternative strategy is in vitro maturation (IVM), which involves the earlier retrieval of immature oocytes at the germinal-vesicle stage followed by maturation in vitro. This method has shown promise, although current evidence from randomized controlled trials is lacking [32].

Furthermore, the exploration of novel pharmacotherapeutic strategies is underway, focusing on emerging therapeutic targets such as neuropeptides, anti-inflammatory agents, and gene therapy [26]. These innovative approaches aim to provide more effective treatments with minimal adverse effects, addressing not only the symptoms of PCOS but also the underlying pathophysiology that affects fertility.

In summary, PCOS poses significant challenges to fertility through its impact on ovulation and hormonal balance. Treatment strategies range from lifestyle changes and pharmacological interventions to advanced ART techniques, each tailored to individual patient needs and reproductive goals. Ongoing research into novel therapeutic targets and techniques continues to evolve, aiming to enhance fertility outcomes for women affected by this complex disorder.

6 Future Directions in Research ​

6.1 Emerging Therapies ​

Polycystic ovary syndrome (PCOS) significantly impacts fertility through various reproductive and metabolic disturbances. It is recognized as the most common cause of anovulatory infertility among women of reproductive age, affecting approximately 5-10% of this population[13]. The disorder is characterized by chronic anovulation, hyperandrogenism, and the presence of multiple cysts in the ovaries, which collectively contribute to impaired reproductive function[14].

The pathophysiology of PCOS is complex and multifaceted, involving hormonal imbalances that disrupt normal ovarian function. Many women with PCOS experience irregular menstrual cycles and anovulation, which directly reduce the likelihood of conception[19]. Moreover, the syndrome is often associated with metabolic issues such as insulin resistance, obesity, and an increased risk of type 2 diabetes, which can further exacerbate reproductive challenges[27].

The quality of oocytes in women with PCOS can also be compromised. Research indicates that alterations in oocyte competence are potential causative factors for subfertility in this population. The competence of oocytes is variable and largely depends on the specific phenotype of PCOS and any comorbidities present[27]. Furthermore, the impact of obesity on reproductive health in women with PCOS cannot be overstated; obesity is linked to worsened hyperandrogenism and metabolic dysfunction, leading to poorer ovulatory performance and lower pregnancy rates[13].

Emerging research is exploring various therapeutic avenues to enhance fertility in women with PCOS. Treatments such as ovulation induction, lifestyle interventions targeting weight loss, and the use of assisted reproductive technologies (ART) are commonly employed. Lifestyle changes have shown efficacy not only in improving metabolic profiles but also in restoring ovulatory function[14]. Additionally, understanding the genetic and epigenetic factors associated with PCOS may lead to more personalized treatment strategies[15].

Future directions in research include investigating the underlying genetic architecture of PCOS and its implications for reproductive health. Studies are focusing on identifying specific genetic variants associated with the disorder and their roles in fertility outcomes[19]. Moreover, there is a growing interest in understanding the transgenerational inheritance of PCOS-related traits and their potential impact on offspring health, which could inform preventive strategies and interventions[15].

In summary, PCOS presents a significant challenge to fertility due to its complex interplay of reproductive and metabolic disturbances. Continued research into the pathophysiology, genetic factors, and emerging therapeutic options is essential for improving reproductive outcomes for women affected by this condition.

6.2 Long-term Health Implications ​

Polycystic ovary syndrome (PCOS) is a complex endocrine disorder that significantly impacts fertility, affecting approximately 5-10% of reproductive-aged women globally. It is characterized by a combination of reproductive and metabolic disturbances, including hyperandrogenism, ovulatory dysfunction, and polycystic ovarian morphology. The implications of PCOS on fertility are multifaceted and can vary widely among individuals.

Research indicates that women with PCOS often experience irregular menstrual cycles, which can lead to anovulation, a primary contributor to infertility. In a study conducted by Hassan and Killick (2003), it was observed that women with polycystic ovaries, particularly those who are symptomatic, face longer times to pregnancy (TTP) and higher risks of subfertility compared to those with normal ovaries. Specifically, factors such as obesity, menstrual disturbances, hirsutism, and acne were linked to significantly reduced fertility, with the relative risk of subfertility increasing with the number of symptoms presented (RR = 2.6 for obesity, RR = 4.6 for menstrual disturbances, etc.) [1].

Additionally, the relationship between PCOS and metabolic syndrome further complicates reproductive outcomes. PCOS is often associated with insulin resistance, which can exacerbate the condition and lead to increased cardiovascular risks and metabolic disorders. The systemic implications of PCOS extend beyond reproductive function, influencing overall health and increasing the likelihood of conditions such as type 2 diabetes [3].

Emerging research also highlights the role of hyperhomocysteinemia (HHcy) in affecting reproductive function. A study by Wang et al. (2024) found that HHcy in mice resulted in reduced fertility, increased ovarian atretic follicles, and decreased oocyte maturation rates. This suggests that metabolic abnormalities linked to PCOS may further compromise oocyte and embryo quality, thus affecting fertility outcomes [33].

The long-term health implications of PCOS are profound. Women with this syndrome face not only challenges related to fertility but also increased risks for various health issues, including cardiovascular diseases, endometrial cancer, and psychological conditions such as anxiety and depression [34]. The complexity of PCOS, with its overlapping reproductive and metabolic issues, underscores the need for personalized treatment approaches and comprehensive healthcare strategies.

Future research directions should focus on elucidating the underlying mechanisms of PCOS, particularly its genetic and environmental interactions, and developing standardized diagnostic criteria. Improved understanding of the diverse phenotypes of PCOS can lead to more effective interventions and management strategies that address both reproductive and metabolic health [35].

In summary, PCOS significantly affects fertility through a combination of hormonal imbalances, metabolic disturbances, and associated health risks. Addressing these factors holistically will be crucial in improving reproductive outcomes and the overall health of women affected by this syndrome.

7 Conclusion ​

Polycystic Ovary Syndrome (PCOS) represents a significant challenge to fertility, primarily due to its association with hormonal imbalances, metabolic dysfunctions, and clinical manifestations such as anovulation and irregular menstrual cycles. The complexity of PCOS requires a multifaceted approach to management, integrating lifestyle modifications, pharmacological treatments, and assisted reproductive technologies to optimize reproductive outcomes. Current research underscores the importance of understanding the interplay between hyperandrogenism, insulin resistance, and obesity, which collectively exacerbate fertility issues. Furthermore, the long-term health implications for women with PCOS necessitate ongoing investigation into personalized treatment strategies that address both reproductive and metabolic health. Future research directions should focus on elucidating the genetic and epigenetic factors contributing to PCOS, as well as the development of novel therapeutic approaches aimed at improving fertility and overall health in affected women. As our understanding of PCOS continues to evolve, it is essential to translate these insights into effective clinical practices that enhance the quality of life for women dealing with this complex disorder.

References ​

  • [1] Mohamed A M Hassan;Stephen R Killick. Ultrasound diagnosis of polycystic ovaries in women who have no symptoms of polycystic ovary syndrome is not associated with subfecundity or subfertility.. Fertility and sterility(IF=7.0). 2003. PMID:14556819. DOI: 10.1016/s0015-0282(03)01010-0.
  • [2] Sigrid Elsenbruch;Susanne Hahn;Daniela Kowalsky;Alexandra H Offner;Manfred Schedlowski;Klaus Mann;Onno E Janssen. Quality of life, psychosocial well-being, and sexual satisfaction in women with polycystic ovary syndrome.. The Journal of clinical endocrinology and metabolism(IF=5.1). 2003. PMID:14671172. DOI: 10.1210/jc.2003-030562.
  • [3] Stephen Corbett;Laure Morin-Papunen. The Polycystic Ovary Syndrome and recent human evolution.. Molecular and cellular endocrinology(IF=3.6). 2013. PMID:23352610. DOI: .
  • [4] Luca Persani;Raffaella Rossetti;Elisa Di Pasquale;Chiara Cacciatore;Stéphane Fabre. The fundamental role of bone morphogenetic protein 15 in ovarian function and its involvement in female fertility disorders.. Human reproduction update(IF=16.1). 2014. PMID:24980253. DOI: 10.1093/humupd/dmu036.
  • [5] V De Leo;M C Musacchio;V Cappelli;M G Massaro;G Morgante;F Petraglia. Genetic, hormonal and metabolic aspects of PCOS: an update.. Reproductive biology and endocrinology : RB&E(IF=4.7). 2016. PMID:27423183. DOI: 10.1186/s12958-016-0173-x.
  • [6] K J Polinski;S L Robinson;D L Putnick;R Sundaram;A Ghassabian;P Joseph;V Gomez-Lobo;E M Bell;E H Yeung. Maternal self-reported polycystic ovary syndrome with offspring and maternal cardiometabolic outcomes.. Human reproduction (Oxford, England)(IF=6.1). 2024. PMID:37935839. DOI: 10.1093/humrep/dead227.
  • [7] C V Bishop;R L Stouffer;D L Takahashi;E C Mishler;M C Wilcox;O D Slayden;C A True. Chronic hyperandrogenemia and western-style diet beginning at puberty reduces fertility and increases metabolic dysfunction during pregnancy in young adult, female macaques.. Human reproduction (Oxford, England)(IF=6.1). 2018. PMID:29401269. DOI: 10.1093/humrep/dey013.
  • [8] Maximiliane Lara Verfürden;Volker Schnecke;Eva Winning Lehmann;Adriana Rendón Guillén;Adam H Balen. Association between weight loss and reproductive outcomes among women with overweight or obesity: a cohort study using UK real-world data.. Human reproduction (Oxford, England)(IF=6.1). 2025. PMID:40618200. DOI: 10.1093/humrep/deaf122.
  • [9] Manuel Luque-Ramírez;Lía Nattero-Chávez;Andrés E Ortiz Flores;Héctor F Escobar-Morreale. Combined oral contraceptives and/or antiandrogens versus insulin sensitizers for polycystic ovary syndrome: a systematic review and meta-analysis.. Human reproduction update(IF=16.1). 2018. PMID:29293982. DOI: 10.1093/humupd/dmx039.
  • [10] Pascal Froment;Ingrid Plotton;Cecilia Giulivi;Stephane Fabre;Rita Khoueiry;Nizar I Mourad;Sandrine Horman;Christelle Ramé;Charlène Rouillon;Jeremy Grandhaye;Yves Bigot;Claire Chevaleyre;Remy Le Guevel;Patricia Mallegol;Ramaroson Andriantsitohaina;Fabrice Guerif;Jérôme Tamburini;Benoit Viollet;Marc Foretz;Joelle Dupont. At the crossroads of fertility and metabolism: the importance of AMPK-dependent signaling in female infertility associated with hyperandrogenism.. Human reproduction (Oxford, England)(IF=6.1). 2022. PMID:35459945. DOI: 10.1093/humrep/deac067.
  • [11] David F Restuccia;Debby Hynx;Brian A Hemmings. Loss of PKBβ/Akt2 predisposes mice to ovarian cyst formation and increases the severity of polycystic ovary formation in vivo.. Disease models & mechanisms(IF=3.3). 2012. PMID:22275470. DOI: 10.1242/dmm.008136.
  • [12] Kyung-Wook Kim. Unravelling Polycystic Ovary Syndrome and Its Comorbidities.. Journal of obesity & metabolic syndrome(IF=7.9). 2021. PMID:34497157. DOI: 10.7570/jomes21043.
  • [13] R Pasquali;A Gambineri;U Pagotto. The impact of obesity on reproduction in women with polycystic ovary syndrome.. BJOG : an international journal of obstetrics and gynaecology(IF=4.3). 2006. PMID:16827825. DOI: 10.1111/j.1471-0528.2006.00990.x.
  • [14] Ivan Araujo Penna;Paulo Roberto Bastos Canella;Carolina Sales Vieira;Marcos Felipe Silva de Sá;Rosana Maria dos Reis;Rui Alberto Ferriani. Cardiovascular risk factors are reduced with a low dose of acarbose in obese patients with polycystic ovary syndrome.. Fertility and sterility(IF=7.0). 2007. PMID:17418836. DOI: 10.1016/j.fertnstert.2006.11.073.
  • [15] Elisabet Stener-Victorin;Qiaolin Deng. Epigenetic inheritance of PCOS by developmental programming and germline transmission.. Trends in endocrinology and metabolism: TEM(IF=12.6). 2025. PMID:39732517. DOI: 10.1016/j.tem.2024.12.002.
  • [16] Xiaoling Ouyang;Qi Zhou;Hong Tang;Linxia Li. Pathogenesis and treatment of obesity-related polycystic ovary syndrome.. Journal of ovarian research(IF=4.2). 2025. PMID:41239503. DOI: 10.1186/s13048-025-01817-w.
  • [17] Heqiu Yan;Li Wang;Guohui Zhang;Ningjing Li;Yuhong Zhao;Jun Liu;Min Jiang;Xinrong Du;Qin Zeng;Dongsheng Xiong;Libing He;Zhuoting Zhou;Mengjun Luo;Weixin Liu. Oxidative stress and energy metabolism abnormalities in polycystic ovary syndrome: from mechanisms to therapeutic strategies.. Reproductive biology and endocrinology : RB&E(IF=4.7). 2024. PMID:39722030. DOI: 10.1186/s12958-024-01337-0.
  • [18] Florentina Duică;Cezara Alina Dănilă;Andreea Elena Boboc;Panagiotis Antoniadis;Carmen Elena Condrat;Sebastian Onciul;Nicolae Suciu;Sanda Maria Creţoiu;Valentin Nicolae Varlas;Dragoş Creţoiu. Impact of Increased Oxidative Stress on Cardiovascular Diseases in Women With Polycystic Ovary Syndrome.. Frontiers in endocrinology(IF=4.6). 2021. PMID:33679617. DOI: 10.3389/fendo.2021.614679.
  • [19] Kateryna Mykhalchenko;Daria Lizneva;Tatiana Trofimova;Walidah Walker;Larisa Suturina;Michael P Diamond;Ricardo Azziz. Genetics of polycystic ovary syndrome.. Expert review of molecular diagnostics(IF=3.6). 2017. PMID:28602111. DOI: 10.1080/14737159.2017.1340833.
  • [20] I Yaish;K Tordjman;H Amir;G Malinger;Y Salemnick;G Shefer;M Serebro;F Azem;N Golani;Y Sofer;N Stern;Y Greenman. Functional ovarian reserve in transgender men receiving testosterone therapy: evidence for preserved anti-Müllerian hormone and antral follicle count under prolonged treatment.. Human reproduction (Oxford, England)(IF=6.1). 2021. PMID:34411251. DOI: 10.1093/humrep/deab169.
  • [21] Norbert Gleicher;David Barad. An evolutionary concept of polycystic ovarian disease: does evolution favour reproductive success over survival?. Reproductive biomedicine online(IF=3.5). 2006. PMID:16790102. DOI: 10.1016/s1472-6483(10)61184-4.
  • [22] Lisa J Moran;Samantha K Hutchison;Robert J Norman;Helena J Teede. Lifestyle changes in women with polycystic ovary syndrome.. The Cochrane database of systematic reviews(IF=9.4). 2011. PMID:21735412. DOI: 10.1002/14651858.CD007506.pub3.
  • [23] Siew S Lim;Samantha K Hutchison;Emer Van Ryswyk;Robert J Norman;Helena J Teede;Lisa J Moran. Lifestyle changes in women with polycystic ovary syndrome.. The Cochrane database of systematic reviews(IF=9.4). 2019. PMID:30921477. DOI: 10.1002/14651858.CD007506.pub4.
  • [24] Rohit Gautam;Pratibha Maan;Anshu Jyoti;Anshu Kumar;Neena Malhotra;Taruna Arora. The Role of Lifestyle Interventions in PCOS Management: A Systematic Review.. Nutrients(IF=5.0). 2025. PMID:39861440. DOI: 10.3390/nu17020310.
  • [25] Yi-Ru Tsai;Yen-Nung Liao;Hong-Yo Kang. Current Advances in Cellular Approaches for Pathophysiology and Treatment of Polycystic Ovary Syndrome.. Cells(IF=5.2). 2023. PMID:37681921. DOI: 10.3390/cells12172189.
  • [26] Kamini R Shirasath;N Zaheer Ahmed;Pawan Kumar;Shah Alam;Ritu Karwasra;Sameer N Goyal;Yogeeta O Agrawal. Unraveling PCOS therapies: Pharmacotherapeutic strategies and emerging therapeutic targets.. Pathology, research and practice(IF=3.2). 2025. PMID:41027241. DOI: 10.1016/j.prp.2025.156245.
  • [27] Stefano Palomba;Jessica Daolio;Giovanni Battista La Sala. Oocyte Competence in Women with Polycystic Ovary Syndrome.. Trends in endocrinology and metabolism: TEM(IF=12.6). 2017. PMID:27988256. DOI: 10.1016/j.tem.2016.11.008.
  • [28] Weiwei Zeng;Yuning Luo;Juanfeng Ou;Dali Gan;Min Huang;Brian Tomlinson;Yiming Jiang. Metformin in polycystic ovary syndrome: unraveling multi-stage therapeutic mechanisms from puberty to long-term health outcomes.. Frontiers in pharmacology(IF=4.8). 2025. PMID:40900830. DOI: 10.3389/fphar.2025.1654372.
  • [29] Sidra Malik;Saira Saeed;Ammara Saleem;Muhammad Imran Khan;Aslam Khan;Muhammad Furqan Akhtar. Alternative treatment of polycystic ovary syndrome: pre-clinical and clinical basis for using plant-based drugs.. Frontiers in endocrinology(IF=4.6). 2023. PMID:38725974. DOI: 10.3389/fendo.2023.1294406.
  • [30] Rita Singh;Surleen Kaur;Suman Yadav;Smita Bhatia. Gonadotropins as pharmacological agents in assisted reproductive technology and polycystic ovary syndrome.. Trends in endocrinology and metabolism: TEM(IF=12.6). 2023. PMID:36863888. DOI: 10.1016/j.tem.2023.02.002.
  • [31] Abeer M Rababa'h;Bayan R Matani;Alaa Yehya. An update of polycystic ovary syndrome: causes and therapeutics options.. Heliyon(IF=3.6). 2022. PMID:36267367. DOI: 10.1016/j.heliyon.2022.e11010.
  • [32] Charalampos S Siristatidis;Nikos Vrachnis;Maria Creatsa;Abha Maheshwari;Siladitya Bhattacharya. In vitro maturation in subfertile women with polycystic ovarian syndrome undergoing assisted reproduction.. The Cochrane database of systematic reviews(IF=9.4). 2013. PMID:24101529. DOI: 10.1002/14651858.CD006606.pub3.
  • [33] Lu Wang;Jinmei Gao;Jie Ma;Jing Sun;Yajie Wang;Jia Luo;Zhaoyang Wang;Hui Wang;Jialing Li;Danyu Yang;Jinfang Wang;Rong Hu. Effects of hyperhomocysteinemia on follicular development and oocytes quality.. iScience(IF=4.1). 2024. PMID:39563894. DOI: 10.1016/j.isci.2024.111241.
  • [34] Linda G Kahn;Alison E Hipwell;Mia Charifson;Rui Ling;Kim N Cajachagua-Torres;Akhgar Ghassabian. Maternal polycystic ovarian syndrome and offspring psychopathology and neurodevelopment.. Human reproduction (Oxford, England)(IF=6.1). 2025. PMID:40380372. DOI: 10.1093/humrep/deaf079.
  • [35] Anagha Joshi. PCOS stratification for precision diagnostics and treatment.. Frontiers in cell and developmental biology(IF=4.3). 2024. PMID:38389707. DOI: 10.3389/fcell.2024.1358755.

MaltSci Intelligent Research Services ​

Search for more papers on MaltSci.com ​

Polycystic Ovary Syndrome · Fertility · Hormonal Imbalances · Metabolic Dysfunction · Infertility

© 2025 MaltSci